Targeting integrins αvβ3 and α5β1 with new β-lactam derivatives

Eur J Med Chem. 2014 Aug 18:83:284-93. doi: 10.1016/j.ejmech.2014.06.041. Epub 2014 Jun 19.

Abstract

The αvβ3 and α5β1 integrins are widely expressed in different cancer types and recognize the tripeptide Arg-Gly-Asp (RGD) motif present in several extracellular matrix proteins. We report here the design, synthesis and biological activity of some new β-lactam derivatives specifically designed to target integrins. The new molecules contain the azetidinone as the only cyclic framework armed with carboxylic acid and amine terminals spaced from 9 to 14 atoms to switch on recognition by integrins. All tested molecules showed a concentration-dependent enhancement in fibronectin-mediated adhesion of K562 and SK-MEL-24 cells; in particular 1, expressed a higher affinity towards α5β1 integrin (EC50 of 12 nM) and 2 was more selective for integrin αvβ3 (EC50 of 11 nM).

Keywords: Agonists; Azetidinones; Cell adhesion; Integrins; Lactams; Peptidomimetics.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Azetidines / chemistry
  • Cell Line, Tumor
  • Drug Design
  • Humans
  • Integrin alpha5beta1 / agonists
  • Integrin alpha5beta1 / metabolism*
  • Integrin alphaVbeta3 / agonists
  • Integrin alphaVbeta3 / metabolism*
  • Ligands
  • Molecular Targeted Therapy*
  • beta-Lactams / chemical synthesis
  • beta-Lactams / chemistry*
  • beta-Lactams / pharmacology*

Substances

  • 2-azetidinone
  • Azetidines
  • Integrin alpha5beta1
  • Integrin alphaVbeta3
  • Ligands
  • beta-Lactams